FDA Clearance Tracker · P230043
Multi-Target Stool DNA (mtsDNA) Test, Cologuard Plus
Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Oct 3, 2024
Approved
Time to decision
286 days
Received Dec 22, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P230043
- Device name
- Multi-Target Stool DNA (mtsDNA) Test, Cologuard Plus
- Applicant
- Exact Sciences Corporation
- Applicant location
- Madision, WI
- Received
- Dec 22, 2023
- Decided
- Oct 3, 2024
- Decision
- Approved
- Supplements
- 10 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
A qualitative in vitro diagnostic test intended for the detection of colorectal neoplasia-associated DNA markers and for the presence of occult hemoglobin in human stool. The Cologuard Plus test is performed on samples collected using the Cologuard Plus Collection Kit. A positive result may indicate the presence of colorectal cancer (CRC) or advance precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard Plus test is indicated to screen adults 45 years or older who are at average risk for CRC. The Cologuard Plus test is not a replacement for diagnostic colonoscopy in high-risk individuals. The Cologuard Plus test is performed at Exact Sciences, Madison, WI.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PHP. The earliest in FDA's data is P130017, decided Aug 11, 2014.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Exact Sciences Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P210040 · Decided Dec 12, 2022 · 349 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.